艾拉莫德对脂多糖诱导的小鼠系统性炎症的保护作用

Iguratimod Diminishes LPS-induced Systemic Inflammation in Mice

研究艾拉莫德对脂多糖(LPS)诱导的小鼠系统性炎症和多器官损伤的保护作用。小鼠腹腔注射LPS 5 mg/kg建立系统性炎症和多器官损伤模型。试验结果显示,与模型组相比,阳性药强的松组(prednisone)和T614中高剂量组动物死亡率、临床症状、脏器系数及组织病理学结果均显著改善;同时血液生化指标(ALT、AST、ALP、BUN、CREA和UA)显著降低(均P<0.01),血液学指标(WBC、RBC、PLT和RET)均与空白对照组动物水平相当。试验结果表明T614对LPS诱导的小鼠系统性炎症和多器官损伤具有保护作用。

To investigate the protective effect of Iguratimod（T614） against lipopolysaccharide（LPS） induced systemic inflammation and multiple organ damage in mice. We established a systemic inflammation and multiple organ damage mouse model by intraperitoneal injection LPS 5 mg/kg. The results showed the death rate, clinical symptoms, organ index and histopathological findings of positive drug control group （prednisone） 5 mg/kg and T614 30 mg/kg and 90 mg/kg dose groups were improved obviously than the model group. The blood biochemical parameters （ALT, AST, ALP, BUN, CREA and UA） were lower obviously than the model group（P〈0.01）, the hematological parameters（WBC, RBC, PLT and RET） were in the same level comparing with the blank control group. The results showed T614 diminishes LPS-induced systemic inflammation and multiple organ damage in mice.